好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Interim Analysis of the Effectiveness of Second-Line Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients Treated with Prior First-Line Treatment, Other Than Natalizumab, in Spain: The Observational, Retrospective NEXT Study
Multiple Sclerosis
(-)
106
Authors/Disclosures
Virginia Meca Lallana
PRESENTER
Virginia Meca Lallana has nothing to disclose.
No disclosure on file
Javier Jose Mallada (Hospital Elda) No disclosure on file
Eugenia Marzo No disclosure on file
Francisco Barrero No disclosure on file
Francisco Javier Ricart Francisco Javier Ricart has received personal compensation for serving as an employee of Novartis. Francisco Javier Ricart has received personal compensation for serving as an employee of Novartis.
No disclosure on file